Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

This study is comparing two approaches before CAR-T cell therapy — a cutting-edge cancer treatment where a patient's own immune cells are modified to attack cancer — in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. One approach uses bridging immunotherapy to keep the disease under control while CAR-T cells are being made; the other skips that bridging therapy. **You may be eligible if...** - You are 18 or older - You have B-cell non-Hodgkin's lymphoma confirmed by biopsy, and it has relapsed or not responded to at least one prior treatment including standard chemotherapy and an anti-CD20 drug - You have not previously received CAR-T cell therapy targeting CD19 - Your organs are functioning well enough to tolerate the treatment - You have sufficient vein access for the cell collection procedure (leukapheresis) **You may NOT be eligible if...** - You have had an allogeneic bone marrow transplant (donor transplant) - You have a history of epilepsy, stroke, dementia, or autoimmune neurological disease - You have another active cancer (with limited exceptions) - You have serious heart failure (NYHA class III–IV) or a heart ejection fraction below 50% - You are allergic to the study treatment components Talk to your doctor to see if this trial is right for you.